MedTrace Logo

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

NCT05696392 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-12-19

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.

Conditions

Interventions

DRUG

ruxolitinib cream

ruxolitinib cream 1.5% will be applied twice daily as a thin film

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-16
Primary Completion
2025-01-22
Completion
2025-01-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05696392 on ClinicalTrials.gov